BidaskClub lowered shares of Aduro BioTech (NASDAQ:ADRO) from a hold rating to a sell rating in a research report released on Tuesday morning.
A number of other equities analysts also recently commented on ADRO. Zacks Investment Research raised Aduro BioTech from a hold rating to a buy rating and set a $8.00 price objective for the company in a research report on Tuesday, July 3rd. Bank of America lowered their price objective on Aduro BioTech from $8.00 to $6.00 and set an underperform rating for the company in a research report on Thursday, August 2nd. Canaccord Genuity reissued a buy rating and set a $30.00 price objective on shares of Aduro BioTech in a research report on Thursday, August 2nd. William Blair reissued a buy rating on shares of Aduro BioTech in a research report on Wednesday, October 3rd. Finally, HC Wainwright set a $10.00 price objective on Aduro BioTech and gave the stock a buy rating in a research report on Thursday, August 2nd. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $13.33.
Shares of Aduro BioTech stock opened at $6.08 on Tuesday. Aduro BioTech has a one year low of $5.10 and a one year high of $10.10. The stock has a market cap of $581.09 million, a PE ratio of -4.27 and a beta of 2.22.
Aduro BioTech (NASDAQ:ADRO) last announced its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($0.31) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.02. Aduro BioTech had a negative return on equity of 44.97% and a negative net margin of 574.11%. The business had revenue of $2.64 million during the quarter, compared to the consensus estimate of $3.74 million. Research analysts predict that Aduro BioTech will post -1.25 EPS for the current year.
In related news, insider Blaine Templeman sold 10,262 shares of the company’s stock in a transaction that occurred on Monday, September 24th. The stock was sold at an average price of $5.81, for a total value of $59,622.22. Following the completion of the transaction, the insider now directly owns 131,119 shares of the company’s stock, valued at $761,801.39. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Elsas Andrea Van sold 10,454 shares of the company’s stock in a transaction that occurred on Tuesday, July 17th. The shares were sold at an average price of $6.96, for a total value of $72,759.84. Following the completion of the transaction, the insider now directly owns 206,215 shares of the company’s stock, valued at $1,435,256.40. The disclosure for this sale can be found here. Insiders sold 123,614 shares of company stock valued at $892,283 over the last ninety days. 5.00% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Swiss National Bank boosted its holdings in Aduro BioTech by 27.5% in the second quarter. Swiss National Bank now owns 73,300 shares of the biotechnology company’s stock valued at $513,000 after purchasing an additional 15,800 shares in the last quarter. Alps Advisors Inc. boosted its holdings in Aduro BioTech by 14.2% in the second quarter. Alps Advisors Inc. now owns 114,257 shares of the biotechnology company’s stock valued at $800,000 after purchasing an additional 14,187 shares in the last quarter. Rhumbline Advisers boosted its holdings in Aduro BioTech by 52.2% in the second quarter. Rhumbline Advisers now owns 60,733 shares of the biotechnology company’s stock valued at $425,000 after purchasing an additional 20,821 shares in the last quarter. Capital Fund Management S.A. acquired a new position in Aduro BioTech in the second quarter valued at approximately $130,000. Finally, Vident Investment Advisory LLC boosted its holdings in Aduro BioTech by 53.9% in the second quarter. Vident Investment Advisory LLC now owns 325,660 shares of the biotechnology company’s stock valued at $2,280,000 after purchasing an additional 114,014 shares in the last quarter. 49.00% of the stock is owned by hedge funds and other institutional investors.
About Aduro BioTech
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
Recommended Story: NASDAQ Stock Market Explained
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.